ID   TU-ECS-1
AC   CVCL_IP26
DR   cancercelllines; CVCL_IP26
DR   Wikidata; Q54973325
RX   PubMed=27889902;
CC   Population: Japanese.
CC   Doubling time: 18.2 +- 2.1 hours (PubMed=27889902).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=27889902).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Ala189Val (c.566C>T); ClinVar=VCV000012382; Zygosity=Unspecified (PubMed=27889902).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=27889902).
CC   Derived from site: In situ; Uterus; UBERON=UBERON_0000995.
DI   NCIt; C42700; Uterine carcinosarcoma
DI   ORDO; Orphanet_213610; Carcinosarcoma of the corpus uteri
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   66Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 19-12-24; Version: 14
//
RX   PubMed=27889902; DOI=10.1007/s13577-016-0154-6;
RA   Chiba Y., Sato S., Itamochi H., Suga Y., Fukagawa T., Oumi N.,
RA   Oishi T., Harada T., Sugai T., Sugiyama T.;
RT   "Establishment and characterization of a novel uterine carcinosarcoma
RT   cell line, TU-ECS-1, with mutations of TP53 and KRAS.";
RL   Hum. Cell 30:140-148(2017).
//